spacer
home > white papers > Faster, Better, Cheaper: Lean as a Driving Force Behind Pharmaceutical Companies’ Growth - TBM Consulting Group
WHITE PAPERS
logo_TBM_Consul.jpg

TBM Consulting Group

phone +49 (0) 69 710 455 172
email info@tbmcg.com
web http://www.tbmcg.com
email TBM Consulting Group Deutschland, Bockenheimer Landstrasse 17/19, 60325 Frankfurt am Main

Faster, Better, Cheaper: Lean as a Driving Force Behind Pharmaceutical Companies’ Growth

The pharmaceutical industry faces countless challenges: patent expirations, weak product development pipelines, downward pricing pressure and an increasingly burdensome regulatory environment. The most important question for companies is now “How can we position ourselves optimally to be successful in the long term?”

Some pharmaceutical companies used the economic downturn in 2009 to embrace measures in the fields of cost reduction and efficiency increases, which can be implemented at short notice. The continuous and consistent implementation of sustainable measures that guarantee stability and form the basis for future growth was not necessarily paramount within this.
Faster, Better, Cheaper: Lean as a Driving Force Behind Pharmaceutical Companies’ Growth
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Wickham Laboratories to present at Cleanroom Technology Conference 2018

We are pleased to announce our CEO, Dr John McKenzie, will be presenting on ‘Microbiological Considerations in Cleanroom Validation’ at the Cleanroom Technology Conference to be held 16th-17th May, 2018.
More info >>


White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>


Industry Events

DIA 2018 Global Annual Meeting

24-28 June 2018, Boston, MA

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe. Designed to drive insights into action by connecting key policy discussions to real-world knowledge that you need to do your job every day, your attendance will accelerate your growth and your organization's performance in the development ecosystem.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement